Avidity Biosciences Inc., a biopharmaceutical company focused on RNA therapeutics, announced new inducement grants under its 2022 Employment Inducement Incentive Award Plan. On May 20, 2025, the company's Human Capital Management Committee granted non-qualified stock option awards for 71,000 shares and 35,000 restricted stock units (RSUs) to sixteen new non-executive employees. These inducement awards are part of the company's efforts to attract new talent and are issued in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $31.64 per share, matching the closing price of Avidity's stock on the Nasdaq Global Market on the grant date. The options and RSUs will vest over four years, contingent upon the employees' continued employment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。